Search Site

Trends banner

Qualcomm to Alphawave for $2.4 bn

The deal makes Alphawave the latest tech company to depart London.

Equinor signs $27 bn gas deal

The 10-year contract was signed with Centrica.

ADNOC Drilling secures $1.15bn contract

The contract for two jack-up rigs begins in the second quarter.

Etihad Q1 profit $187 million

This is a 30% YoY increase over Q1 2025.

Yalla Group Q1 revenue $83m

Net income rose to $36.4 million, a 17% YoY increase.

Sanofi 2022 net profit at $7.3bn

1 min read
Sanofi's earnings per share rose by 17.1 percent to US$9 but Sanofi forecast low single-digit growth this year. (AFP)
  • Sanofi is aiming for US$10.9 billion in sales of Dupixent this year.
  • The company's net profit rose by eight percent in 2022.

PARIS, FRANCE – French pharmaceutical giant Sanofi forecast slower earnings growth for 2023 on Friday after profits jumped in 2022 on the back of popular eczema and asthma drug Dupixent.

The company’s net profit rose by eight percent to US$7.3 billion (6.7 billion euros) last year.

Its earnings per share, or profits divided by outstanding shares, rose by 17.1 percent to US$9 (8.26 euros), but Sanofi forecast “low single-digit” growth this year.

Sanofi shares fell following the announcement.

The company’s Dupixent treatment has been a huge success for Sanofi, raking in US$9 billion (8.3 billion euros) in sales last year.

“Dupixent and Vaccines continue to be our leading growth drivers,” Sanofi chief executive Paul Hudson said in a statement.

Sanofi is aiming for US$10.9 billion (10 billion euros) in sales of Dupixent this year.